



ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly

Sabina A. Guler¹, Sara Cuevas-Ocaña², Mouhamad Nasser³, Wim A. Wuyts⁴, Marlies S. Wijsenbeek⁵, Antoine Froidure⁶, Elena Bargagli⁷, Elisabetta A. Renzoni⁸, Marcel Veltkamp^{9,10}, Paolo Spagnolo¹¹, Hilario Nunes¹², Cormac McCarthy¹³, Maria Molina-Molina¹⁴, Francesco Bonella¹⁵, Venerino Poletti¹⁶, Michael Kreuter¹⁷, Katerina M. Antoniou¹⁸ and Catharina C. Moor⁵

¹Dept of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ²Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham, UK. ³Dept of Respiratory Medicine, National Reference Center for Rare Pulmonary Diseases, Hospices Civils de Lyon, Lyon, France. ⁴Unit for Interstitial Lung Disease, Dept of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium. ⁵Center for Interstitial Lung Diseases and Sarcoidosis, Dept of Respiratory Medicine, Erasmus MC–University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁶Service de Pneumologie, Cliniques Universitaires Saint-Luc and Institut de Recherche Expérimentale, UCLouvain, Brussels, Belgium. ⁷Dept of Medical Sciences, Surgery and Neurosciences, Respiratory Medicine, Siena University, Siena, Italy. ⁸Interstitial Lung Disease Unit, Royal Brompton and Harefield (Guy's and St Thomas' NHS Foundation Trust), Margaret Turner Warwick Centre for Fibrosing Lung Diseases, NHLI, Imperial College, London, UK. ⁹Interstitial Lung Diseases Centre of Excellence, St Antonius Hospital, Nieuwegein, The Netherlands. ¹⁰Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. ¹¹Respiratory Disease Unit, Dept of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy. ¹²Service de Pneumologie, Centre de Référence des Maladies Pulmonaires Rares, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Université Sorbonne Paris Nord, Bobigny, France. ¹³UCD School of Medicine, Education and Research Centre, St Vincent's University Hospital, Dublin, Ireland. ¹⁴Dept of Pneumology, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain. ¹⁵Center for Interstitial and Rare Lung Diseases, Ruhrlandklinik University Hospital, Duisburg-Essen University, Essen, Germany. ¹⁶Dipartimento Malattie dell'Apparato Respiratorio e del Torace Ospedale GB Morgagni-Forlì (FC)/University of Bologna, Bologna, Italy. ¹⁷Center for Interstitial and Rare Lung Diseases, and Interdisciplinary Center for Sarcoidosis, Pneumology, Thoraxklinik, University Hospital Heidelberg and German Center for Lung Research, Heidelberg, Germany. ¹⁸Laboratory of Molecular and Cellular Pneumology Laboratory, Dept of Respiratory Medicine, School of Medicine, University of Crete, Crete, Greece.

Corresponding author: Catharina C. Moor (c.moor@erasmusmc.nl)



Shareable abstract (@ERSpublications)

This article highlights scientific advances in the field of ILD presented at #ERSCongress 2021, and provides valuable new insights into disease pathophysiology, potential therapeutic targets and disease course of different ILDs <https://bit.ly/3ynCMTf>

Cite this article as: Guler SA, Cuevas-Ocaña S, Nasser M, *et al.* ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly. *ERJ Open Res* 2022; 8: 00640-2021 [DOI: 10.1183/23120541.00640-2021].

Copyright ©The authors 2022

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 16 Nov 2021
Accepted: 4 Dec 2021



Abstract

This article provides an overview of scientific highlights in the field of interstitial lung disease (ILD), presented at the virtual European Respiratory Society Congress 2021. A broad range of topics was discussed this year, ranging from translational and genetic aspects to novel innovations with the potential to improve the patient pathway. Early Career Members summarise a selection of interesting findings from different congress sessions, together with the leadership of Assembly 12 – Interstitial Lung Disease.

Introduction

The field of interstitial lung diseases (ILDs) has rapidly evolved in recent years, with many exciting new developments. During the European Respiratory Society (ERS) Congress 2021 many oral presentation and e-poster sessions were dedicated to ILD. The programme also included interesting expert view, guideline, state-of-the-art and “hot topic” sessions on the new guidelines for sarcoidosis, holistic care in ILD, post-COVID ILD, biomarkers, pulmonary hypertension in ILD, the association between lung cancer and fibrotic ILD, and rare lung diseases.

This year's oral presentation sessions included genetic and translational aspects, new innovations and treatment options, better understanding of pathogenesis and disease course, novel approaches to diagnosis, and prognostic challenges in ILD, as well as epidemiology and outcomes in rare lung diseases.

This article summarises the personal scientific highlights of the authors across all four groups of Assembly 12: Group 12.01 “Idiopathic interstitial pneumonias”, Group 12.02 “ILDs/diffuse parenchymal lung diseases (DPLDs) of known origin”, Group 12.03 “Sarcoidosis and other granulomatous ILDs/DPLDs” and Group 12.04 “Rare ILDs/DPLDs”.

Idiopathic interstitial pneumonias

Many challenges and opportunities in the field of idiopathic interstitial pneumonias were discussed during this year’s ERS Congress, including diagnostic challenges, the need for better treatment options and the impact of comorbidities. Other important topics of discussion were the prediction and early identification of disease progression in patients with pulmonary fibrosis.

Several studies evaluated potential noninvasive and simple solutions to ILD diagnosis. Qiu *et al.* [1] identified a differentially expressed immune-related gene panel from bronchoalveolar lavage (BAL) samples of idiopathic pulmonary fibrosis (IPF) patients and healthy individuals, from which *CXCL14*, *SLC40A1*, *RNASE3*, *CCR3* and *RORA* were used to build a prognostic signature for survival. This five-gene-based signature differentiated significantly between high- and low-risk patient groups (area under the curve (AUC) 0.837). At a protein level, a novel inverse association between pro-fibrotic cytokines and antimicrobial peptides (AMPs) in BAL was identified [2]. The different AMP profiles in BAL of patients with IPF and other fibrotic ILDs compared with nonfibrotic patients might open up new possibilities for early diagnosis of patients at risk. At cellular levels, *in vitro* and *in vivo* studies showed an accumulation of senescent cells and demonstrated a reduction of natural killer (NK) cells in the IPF lung due to a deficient lung recruitment capacity, resulting in an increase of NK cells in the blood [3]. Of interest at a clinical level, NISHIKIORI *et al.* [4] developed an artificial intelligence (AI) software to detect interstitial pneumonias from chest radiographs. This refined AI algorithm was able to distinguish chest radiographs of patients with progressive fibrosing ILD *versus* other abnormal findings with 87% accuracy, and fibrosing ILDs *versus* normal chest radiographs with 95% accuracy. This highlights the potential of AI to assist in the identification and monitoring of ILDs.

Given the frequently prolonged time from symptoms to diagnosis, it is important to assess disease behaviour early in the peri-diagnostic period in patients with suspected ILD. The STARLINER study found that during this period IPF patients had accelerated worsening of some patient-reported outcomes (PROs) compared to non-IPF ILD patients. Thus, PRO results can potentially facilitate the diagnosis of IPF in the early stages of disease [5]. In addition, a multicentre registry study identified that patients with suspected familiar IPF presented with similar lung function decline and prognosis compared to patients with sporadic IPF, further emphasising the importance of early referral [6].

Because currently available antifibrotic treatments do not stop lung function decline, more studies are urgently needed to identify new therapeutic compounds. MATRALIS *et al.* [7] developed two biosynthetic thyroid receptor beta agonists (thyromimetics), which showed therapeutic activity against bleomycin-induced lung injury *in vivo*. Thus, thyromimetics may be a potential new therapy for pulmonary fibrosis in the future. The multinational phase II PINTA study assessed the efficacy and safety of GLPG1205 in IPF *versus* placebo. GLPG1205 is a selective G-protein-coupled receptor 84 antagonist, which inhibits monocyte and neutrophil migration and activation. The use of GLPG1205 resulted in a numerically but not significantly smaller decline in forced vital capacity (FVC) (–34 mL *versus* –76 mL) after 26 weeks. No relevant safety signals were observed for GLPG1205 alone or with pirfenidone, but higher rates of early discontinuation were observed for the combination of GLPG1205 and nintedanib [8]. Despite these results, further development of GLPG1205 has been discontinued.

Current treatments are often associated with adverse events, sometimes leading to reduced dosage or treatment breaks. Importantly, PORSE *et al.* [9] showed that patients receiving reduced nintedanib or pirfenidone treatment had a similar survival compared to patients receiving full treatment doses, with all treated participants experiencing an increased survival compared to the no treatment group. A French multicentre phase II randomised controlled trial evaluated the efficacy and safety of cyclophosphamide added to glucocorticoids in 120 patients with acute exacerbation of IPF. The 3-month all-cause mortality was 45% in patients treated with cyclophosphamide *versus* 31% in the placebo group (p=0.1). These data provide evidence against the use of cyclophosphamide for acute exacerbations of IPF [10].

In addition to genetic predisposition and ageing, environmental factors such as long-term exposure to air pollution constitute risk factors for acute exacerbations and disease progression in IPF. TOMOS *et al.* [11] reported that increased concentrations of traffic-related air pollutants (*e.g.* O₃) were associated with changes in IL-4, IL-13 and osteopontin inflammatory mediators involved in lung repair mechanisms.

A retrospective, multicentre study including 3178 patients with IPF found that 1 in 10 of these patients developed lung cancer. IPF patients with lung cancer had a significantly worse prognosis than those without this comorbidity [12]. Aligned with these results, a bioinformatic analysis by Li *et al.* [13] identified that several differentially expressed genes between IPF and healthy BAL samples shared PD-L1 expression and PD-1 checkpoint pathways with cancer. These results further support lung cancer screening in IPF patients, and vice versa, and might help uncover potentially new treatments for these patients. Further studies identifying personalised approaches to the diagnosis and management of patients with IPF and lung cancer are urgently needed.

Although IPF patients have the worst survival, all ILDs can develop progressive fibrosis (PF-ILD). According to the EXCITING registry, PF-ILDs are characterised by a reduced likelihood of survival compared with stable ILDs [14]. Therefore, finding biomarkers that identify patients at higher risk of progressive fibrosis is a huge unmet need. Circulating pneumoproteins like KL-6 seem to be promising in stratifying ILD patients at risk of developing progression at 1 year, according to the preliminary results of the multicentre international VAMOS study [15]. Easily available peripheral monocytes have also been investigated in a subgroup analysis of the INBUILD trial and show a good correlation with survival and disease progression [16]. An association between the TERT_rs2736100 polymorphism and PF-ILD was identified by Dos Reis Estrella *et al.* [17] in patients with familial interstitial pneumonia.

Another interesting study suggested that telomere-related mutations may cause pulmonary fibrosis indirectly by altering the heritable trait telomere length. Thus, it was suggested that first-degree family members with short telomere syndromes could be screened despite having no mutations [18]. During an exciting discussion, the need to incorporate genetic data into ILD clinical practice to better predict individual disease progression was emphasised.

ILDs/DPLDs of known origin

Many interesting presentations focused on ILDs of known origin, with the majority presenting findings on connective tissue disease (CTD)-associated ILDs.

With the aim of improving the diagnosis of ILD in systemic sclerosis (SSc), a panel of serum biomarkers was investigated in two Australian SSc centres. Of the 28 analysed biomarkers, SP-D, Ca15-3 and ICAM-1 were kept in the models. After adjustment for age, sex, smoking status and FVC % predicted (% pred), the combination of these markers was associated with a high likelihood for ILD, and the severity of ILD [19]. Another group confirmed the prognostic significance of the serum biomarker CCL18 in SSc-ILD. The CCL18 SNP rs2015086 was associated with CCL18 serum levels, but not with mortality in their population [20]. A Norwegian group investigated the progression of subclinical CTD-ILD, which was defined as ILD without respiratory symptoms, FVC >80% pred, and a semi-quantitative radiological ILD extent <5%. The progression of the subclinical (n=67) and clinical (n=231) ILD subgroups were compared; over a median observation time of 4.5 years, 51% of the clinical, but also 38% of the subclinical CTD-ILD patients showed progression. These findings challenge the typical “watchful waiting” management approach in the subclinical CTD-ILD population [21]. The need for standardisation of high-resolution computed tomography (HRCT) scans in SSc-ILD was emphasised by a Swedish group who showed different extents of ground glass depending on whether scans were performed in prone position, supine position, or after 10 breaths with a positive expiratory pressure device [22].

A variety of research questions were also studied in patients with rheumatoid arthritis (RA) and other CTD-ILDs. A cohort of 83 CTD-ILD patients in Sri Lanka included 53% with RA-ILD, of whom 56% were women and 73% had a radiological nonspecific interstitial pneumonia pattern, unlike the typical male RA-ILD and usual interstitial pneumonia (UIP) predominance in other RA-ILD cohorts [23]. RA-ILD incidence trends were analysed in Olmsted County (USA), where 1248 RA-ILD cases in two time periods (1955–1994 and 1999–2014) were identified. Unlike the previously reported declining incidence of other extra-articular RA manifestations, the incidence of RA-ILD did not decline over these six decades. Nevertheless, we should keep in mind a potential impact of the more frequent use of chest computed tomography (CT) scans and probably more sensitive detection of RA-ILD over time [24]. Radiological quantification of RA-ILD (reticulations and traction bronchiectasis) for prognostication was evaluated by a Korean group. Patients with and without $\geq 12\%$ lung fibrosis on CT had a 5-year mortality of 50% and 17%, respectively [25]. A Belgian group reported 89 out of 1500 RA patients to have ILD, with 3.8% of the total RA and 29% of the RA-ILD population presenting with a progressive phenotype [26]. Progressive pulmonary fibrosis was also investigated retrospectively in a French cohort of 73 patients with Sjögren’s syndrome-associated ILD. Despite immunosuppressive therapy, 43% of the patients were reported to have an FVC decline $\geq 10\%$ at follow-up, with survival rates of 80% at 5 years and 62% at 10 years. However,

given the nature of this clinical cohort, it is possible there was a selection bias of patients with a progressive disease course [27].

Two Portuguese groups reported prognostic factors in hypersensitivity pneumonitis (HP): in a cohort of 14 patients with chronic HP, a radiological UIP pattern and a higher gender–age–physiology (GAP) index were associated with a higher mortality risk [28]. In 86 multidisciplinary discussion-diagnosed HP cases with a radiological UIP pattern, one-third had a progressive disease behaviour despite immunosuppressive therapy. In this progressive subgroup the proportion of patients without an identified antigen was higher, with lower FVC % pred, and more advanced fibrosis on CT scan compared to the nonprogressive subgroup. This study nicely describes that there is significant heterogeneity in disease behaviour in fibrotic HP patients, even when a UIP pattern is present [29].

To facilitate the diagnosis of asbestosis, a Dutch group created an AI-supported system that integrates information from chest CT scans and pulmonary function tests. In a training set (311 patients) and a test set (88 patients), its diagnostic accuracy against the reference standard (3/3 pulmonologists agreeing on asbestosis) was tested. Besides a remarkable performance of the AI algorithm (AUC 0.87), diffusing capacity of the lungs for carbon monoxide (D_{LCO}) alone also had a similarly good diagnostic performance (AUC 0.85). The validation and incremental benefit of the AI system is still work in progress [30].

A very relevant topic during this COVID-19 era is the impact of COVID-19 on patients with ILD. The EUSTAR registry reported 90 SSc-ILD patients with COVID-19, of whom 19% were deceased and an additional 10% needed mechanical ventilation or extracorporeal membrane oxygenation after a median follow-up of 5.5 weeks, emphasising the potential severity of COVID-19 in patients with SSc-ILD [31]. A Japanese group compared COVID-19 patients with (n=26) and without (n=52, age- and sex-matched) pre-existing ILD, and found that noninvasive ventilation (31% *versus* 2% of cases) and tocilizumab treatment (27% *versus* 8% of cases) were used more frequently in ILD patients, without differences in other management approaches. Mortality rate was higher in ILD compared to the control group (11.5% *versus* 3.8%) [32].

In a pro–con debate, Prof. Bruno Crestani and Prof. Sara Tomassetti discussed the timely topic of post-COVID ILD syndrome. Both experts agreed that severe COVID-19 pneumonia can induce a pro-fibrotic condition and development of lung fibrosis in some cases. Prof. Crestani talked about common biological pathways and similarities in ageing-associated risk factors for post-COVID fibrosis and IPF. Consequently, he argued that similar management approaches should be considered. Prof. Tomassetti proposed five different phenotypes of post-COVID ILD, with the most common presenting with nonspecific interstitial pneumonia/organising pneumonia patterns and a likely underlying auto-inflammatory pathogenesis. Both speakers emphasised that with the currently unknown significance and risk for progression, more research is needed before advocating specific pharmacological treatment for post-COVID ILD.

Sarcoidosis and other granulomatous ILDs/DPLDs

A whole session of the conference was dedicated to the new ERS guideline on management and treatment of sarcoidosis, published in 2021 [33]. Besides the specific recommendations for treatment of pulmonary, skin, cardiac and neurological sarcoidosis, an important part of the discussion was dedicated to treatment indication. Treatment should only be introduced if there is a danger of death, permanent disability or an unacceptable loss of quality of life. Predictors of mortality include presence of pulmonary hypertension, >20% fibrosis on HRCT, composite physiological index >40 or D_{LCO} <40%, or dilatation of the pulmonary artery. The risk of undertreatment *versus* overtreatment should always be carefully evaluated.

Most presentations in this group focused on better understanding of sarcoidosis. A few studies aimed to gain better insights into disease pathogenesis and identify new therapeutic targets. One study demonstrated that neuropilin-2 (NRP2) is a promising new therapeutic target in pulmonary sarcoidosis [34]. NRP2 plays an important role in the regulation of inflammatory responses and is highly expressed in granulomas found in the lungs of sarcoidosis patients, especially on alveolar macrophages and $CD4^+$ T cells. The immunomodulatory protein ATYR1923 selectively binds to NRP2 and reduced the number of alveolar macrophages and $CD4^+$ cells in two different mouse lung inflammatory models. Moreover, ATYR1930, which contains the same immunomodulatory domain as ATYR1923, reduced granuloma formation in an *in vitro* model [34]. Results of a phase I/II clinical trial in patients with pulmonary sarcoidosis are expected soon (NCT03824392).

A Dutch group investigated the role of the mechanistic target of rapamycin 1 (MTORC1) signalling pathway in granuloma formation in sarcoidosis and other granulomatous disorders. Tissue of 74 sarcoidosis patients, 19 patients with HP, and seven patients with granulomatosis with polyangiitis (GPA), were

collected. Thirty-two (43%) of the sarcoidosis patients had an active MTORC1 signalling pathway, *versus* 31% in other ILDs ($p=0.63$). MTORC1 activation was not associated with disease behaviour but could potentially be a therapeutic target in a subset of patients [35].

Multiple antigens have been proposed as potential trigger for sarcoidosis, including different environmental factors. The French RespiRare network evaluated the association between mineral dust exposure and paediatric sarcoidosis. Parents of patients with paediatric sarcoidosis ($n=36$), healthy controls ($n=36$) and sickle-cell disease controls ($n=21$) completed an environmental questionnaire on direct and indirect exposures. The indirect exposure scores (*i.e.* occupational exposure of the parents) were higher in patients with sarcoidosis than in both control groups, particularly exposure to metal dust, talc or abrasive agents, and cleaning with scouring products. The authors conclude that there may be a role of early exposures in the pathophysiology of sarcoidosis [36]. An interesting question is whether different exposures are related to specific organ involvement. In a retrospective study, the medical records of 238 patients with sarcoidosis were screened to collect data on exposures. Patients with sarcoidosis limited to the lungs were more frequently exposed to inorganic dust (*e.g.* silica, metal). Interestingly, patients with liver and spleen involvement were more likely to have contact with livestock or jobs with close human contacts, suggesting an antigen that disseminates systemically. Finally, patients with eye involvement were more likely to be active smokers. These results suggest that different exposures may lead to different sarcoidosis phenotypes, although the clinical implications still need to be addressed in future studies [37].

Besides environmental exposures, a modified microbiome could also be involved in sarcoidosis disease pathogenesis. One study focused on the differences in bacterial and fungal microbiome between patients with sarcoidosis ($n=35$) and healthy controls ($n=35$). The bacterial taxonomic distribution in both oral wash and BAL fluid was similar in both study groups, but bacterial diversity was lower in sarcoidosis patients. Notably, fungal taxonomic distribution was significantly different between the groups. For example, aspergillus was the most dominant genus in BAL samples of sarcoidosis patients, but undetectable in controls. Whether the microbiome is associated with disease course, and could be a novel treatment target for sarcoidosis, still needs to be elucidated [38].

Besides identification of new therapeutic targets, there is also a major need to optimise first-line treatment and tapering regimes, as these are currently largely based on expert opinion. A multicentre prospective observational study assessed the long-term response to prednisone treatment in newly treated patients with pulmonary sarcoidosis. Prednisone was initiated at 40 mg and tapered to 10 mg at week 10. In this study cohort ($n=25$), FVC and D_{LCO} improved significantly between baseline and month 1 (change in FVC % pred: $+11.5\pm 8.5\%$, $p<0.001$, change in D_{LCO} % pred: $+12.5\pm 7.8\%$, $p<0.001$). After month 1, lung function parameters remained stable up until 12 months. The same trends were found for dyspnoea, fatigue and quality of life measured with the King's Sarcoidosis Questionnaire. Importantly, mean weight increase during the 12 months was 8.2 kg (SD 6.2). These results might guide future trial design and optimise treatment schedules [39].

A frequently used third-line treatment option for sarcoidosis is infliximab, a TNF-alpha inhibitor. A retrospective study ($n=95$) evaluated the effects of infliximab treatment on symptoms of small fibre neuropathy (SFN), using the SFN screening list. In patients with improved and stable SFN symptoms, inflammatory activity on fluorodeoxyglucose-positron emission tomography scan significantly decreased, whereas inflammation did not decrease in patients with worsened SFN symptoms. This implies that persistent inflammation may be related to SFN symptoms [40]. Improving treatment options for this debilitating symptom is an important field for future study, especially because the current sarcoidosis guidelines cannot provide a recommendation for treatment of SFN symptoms due to a lack of evidence [33].

Finally, a study in 200 sarcoidosis patients focused on factors influencing cough, measured with the Leicester Cough Questionnaire. A higher body mass index and lower forced expiratory volume in 1 s (FEV_1) was associated with worse cough, indicating that targeting airway obstruction and weight may potentially improve cough symptoms in sarcoidosis [41].

Rare ILDs/DPLDs

This year's ERS Congress programme on rare ILDs and DPLDs primarily encompassed clinical research, providing new insights into clinical and radiological manifestations, as well as phenotyping under-recognised entities.

An Italian retrospective cohort in patients with pulmonary alveolar proteinosis (PAP) aimed to identify predictors for fibrotic evolution. Out of 64 patients included, 12 developed pulmonary fibrosis within

8 years of follow-up. Distinct clinical and therapeutic modalities have been identified among patients with fibrotic and nonfibrotic groups. The fibrotic group had a slightly female predominance (58.3%), with a mean age at diagnosis of 46 years. Two-thirds of patients underwent at least one session of whole lung lavage (WLL); 44% had more than one session and in 50% of cases WLL was followed by inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF). In contrast, the nonfibrotic group had a male predominance (73%) and younger age at diagnosis (41 years). Around 73% had received one session of WLL and 40% had received more sessions. In only 23% of cases was WLL followed by inhaled GM-CSF. In a multivariate regression analysis, D_{LCO} ($p=0.002$) and partial pressure of oxygen ($p=0.011$) at diagnosis were significantly associated with fibrosis development [42].

In a small single-centre Spanish retrospective cohort of lymphangioleiomyomatosis (LAM) (sporadic LAM ($n=10$ patients) and associated with tuberous sclerosis complex (TSC LAM); $n=8$ patients), sporadic LAM patients were older at diagnosis (55 *versus* 34 years old), with 44% of patients having obstructive lung physiology with mean FEV_1 of 69% of predicted. The mean annual FEV_1 and D_{LCO} decline was 1.4% and 2.4%, respectively. mTOR inhibitors were used in 61%. Sporadic LAM had worse prognosis: one patient underwent lung transplantation and two other patients died during a mean follow-up of 15 years [43]. Another small retrospective Portuguese cohort of 12 patients with LAM evaluated medium-term tolerance of mTOR inhibitors. They found a maintained positive effect of sirolimus at 1 and 2 years of follow-up in treated patients ($n=8$), with good drug tolerance and no side-effects. These results support the long-term use of sirolimus in patients with LAM [44].

A British case series of 10 patients with nitrofurantoin-induced ILD aimed to describe this neglected entity of drug-induced ILD. The median age of women receiving nitrofurantoin for recurrent urinary tract infection was 80 years. The mean duration between nitrofurantoin initiation and ILD diagnosis was 17 months. The mean blood eosinophil count was $0.19 \times 10^9/L$ with mean FVC at presentation of 80% pred. The HRCT showed peribronchovascular ground glass and septal thickening in the majority of patients, while isolated consolidations and the UIP pattern was less commonly observed. Nitrofurantoin discontinuation led to improvement in 60% of cases. Glucocorticoids were used in four patients because of persisting ILD despite nitrofurantoin discontinuation [45].

The OrphaLung Network in France for rare pulmonary diseases presented a large retrospective cohort on chronic idiopathic bronchiolitis (CIB), a rare form of chronic and irreversible bronchiolitis in adults. A total of 71 cases with CIB were identified using radiological and histological criteria for evidence of bronchiolitis. Patients were included if they had direct signs of bronchiolitis on HRCT of the chest (tree in bud, branched V- or Y-shaped infiltrates, centrilobular micronodules) or, if available, when lung biopsy showed idiopathic bronchiolitis. The mean age at diagnosis was 52 (± 14) years with a female predominance (71%). Only 41% of patients had history of previous smoking. Obstructive lung physiology ($FEV_1/FVC < 0.7$) was present in 69% of cases. Direct HRCT signs were present in 81% of patients. Evidence of bronchiolitis was seen in all but one biopsied patient (27 patients, lymphocytic [8], follicular [7], constrictive [7], granulomatous [3]). Long-acting beta₂ agonists and inhaled corticosteroids were used in 77% and 73%, respectively. Half of patients were treated with macrolides at one point during their follow-up. Macrolide use was not associated with better outcome. Oral steroids and other immunosuppressive medication were only used in 45% and 12%, respectively. The mean duration of follow-up was 5.1 (± 4.4) years. During follow-up 13 patients developed chronic respiratory failure, one patient received lung transplantation and five patients died [46].

In parallel, the same network reported the largest series until now on patients with pulmonary light chain deposition disease (LCDD), an extremely rare and under-recognised cause of cystic lung disease and bronchiectasis. Thirty-one patients were included in the analysis, of which 68% were female, and 67% were (former) smokers. The mean age at first presentation was 43.5 (± 11.4) years and 50 (± 10.7) years at diagnosis. Dyspnoea (93%) and cough (80%) were the most common symptoms. Haemoptysis was reported by 30% of patients. Obstructive lung physiology ($FEV_1/FVC < 0.7$) was present in 45% with a mean FEV_1 of 86% ($\pm 26\%$) of predicted. D_{LCO} was reduced in 90% of cases. Plasma kappa light chains were increased in 87%, while no patients had increased lambda light chains. The diagnosis was obtained by surgical lung biopsy (36%), post lung transplantation (32%) and bronchial biopsy (26%). The majority of patients had mixed cystic and bronchiectatic forms. The mean annual FEV_1 decline was 127 mL/year. Different chemotherapeutic strategies were used, aimed at reducing secretion of light chains. Unfortunately, there was no apparent efficacy. At the end of the study period, 15 patients underwent bilateral lung transplantation and three patients died. The median transplantation-free survival was 9 years [47].

Concluding remarks

This article highlights scientific advances in the field of ILD presented at the ERS International Congress 2021. The meeting provided the community with valuable new insights into disease pathophysiology, potential therapeutic targets and disease course of different ILDs. Moreover, this year's congress showed that novel approaches are emerging to enhance early diagnosis and improve care for patients with ILD. We welcome everyone to join and contribute to next year's ERS Congress.

Provenance: Commissioned article, peer reviewed.

Conflict of interest: S.A. Guler reports payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Boehringer Ingelheim and Hoffmann-La Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim (disclosures made outside the submitted work). S. Cuevas-Ocaña reports receiving support for attending meetings and/or travel from the ERS (disclosure made outside the submitted work). M. Nasser reports receiving consulting fees from Boehringer Ingelheim, AstraZeneca, Hoffman-La Roche and Chugai, outside the submitted work. W.A. Wuyts reports grants or contracts received from Roche, Boehringer Ingelheim, Galapagos, the NIH and Fund Scientific Research Flanders (disclosures made outside the submitted work). M.S. Wijsenbeek reports receiving grants or contracts from Hoffmann-La Roche and Boehringer Ingelheim; consulting fees from Roche, Boehringer Ingelheim, Galapagos, Bristol Myers Squibb, Galecto and Respivant; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Hoffmann-La Roche and Novartis; support for attending meetings and/or travel from Boehringer Ingelheim and Hoffmann-La Roche; and participation on a Data Safety Monitoring Board for Savara and Galapagos. Unpaid positions: Chair of the Idiopathic Interstitial Pneumonia Group of the ERS; member of the board of the Netherlands Respiratory Society; member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation; Chair of the educational committee of the European Reference Network for Rare Lung Diseases; and advisory board of the Dutch lung fibrosis and sarcoidosis patient associations (disclosures made outside the submitted work). A. Froidure reports grants or contracts received from Roche and Boehringer Ingelheim; and consulting fees received from Boehringer Ingelheim and Roche (disclosures made outside the submitted work). E. Bargagli has nothing to disclose. E.A. Renzoni reports grants or contracts received from Boehringer Ingelheim; consulting fees received from Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Roche and Chiesi; and support for attending meetings and/or travel received from Boehringer Ingelheim (disclosures made outside the submitted work). M. Veltkamp reports receiving consulting fees from Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Chiesi Pharmaceutical; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim and the COLD study (disclosures made outside the submitted work). P. Spagnolo reports grants or contracts received from PPM Services, Roche and Boehringer Ingelheim; consulting fees received from PPM Services, Chiesi, Novartis and Pieris; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Roche and Chiesi; support for attending meetings and/or travel received from PPM Services and Boehringer Ingelheim; and participation on a Data Safety Monitoring Board or Advisory Board for Galapagos (disclosures made outside the submitted work). H. Nunes reports receiving consulting fees from Boehringer Ingelheim, Roche and Genentech; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Roche and Genentech; support for attending meetings and/or travel received from Boehringer Ingelheim, Roche and Genentech; participation on a Data Safety Monitoring Board or Advisory Board for Galapagos and Actelion Pharmaceuticals; and was an investigator of clinical trials for Sanofi, Gilead, Novartis, Galecto Biotech AB and BMS (disclosures made outside the submitted work). C. McCarthy reports receiving grants or contracts from Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Roche Ltd and Aerogen; support for attending meetings and/or travel received from Boehringer Ingelheim and Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Savara Inc. (disclosures made outside the submitted work). M. Molina-Molina reports grants or contracts received from Roche and Boehringer Ingelheim; consulting fees received from Esteve-Teijin, Ferrer and Chiesi; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Boehringer Ingelheim; and support for attending meetings and/or travel received from Boehringer Ingelheim (disclosures made outside the submitted work). F. Bonella reports receiving consulting fees from Boehringer Ingelheim and Savara Pharma; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Fujirebio, Galapagos NV and Roche; support for attending meetings and/or travel received from Boehringer Ingelheim and Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Bristol Myers Squibb, Fujirebio, Galapagos NV, GlaxoSmithKline, Roche and Takeda (disclosures made outside the submitted work).

V. Poletti has nothing to disclose. M. Kreuter reports receiving grants or contracts from Roche and Boehringer Ingelheim; consulting fees received from Roche, Boehringer Ingelheim and Galapagos; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events received from Roche and Boehringer Ingelheim (disclosures made outside the submitted work). K.M. Antoniou reports receiving consulting fees from Boehringer Ingelheim and Roche; payment of honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events for Boehringer Ingelheim and Roche; and support for attending meetings and/or travel received from Boehringer Ingelheim and Roche; she is head of ERS Assembly 12 (disclosures made outside the submitted work). C.C. Moor reports receiving grants or contracts from Roche and Boehringer-Ingelheim; and speaker fees from Roche and Boehringer-Ingelheim. All grants and fees were paid to her institution (disclosures made outside the submitted work).

References

- 1 Qiu L, Gong G, Zang G. A novel prognostic signature based on five-immune-related genes for idiopathic pulmonary fibrosis. *Eur Respir J* 2021; 58: Suppl. 65, OA4327.
- 2 Osuna Gómez R, Orozco Echevarria S, Millán Billi P, et al. Profile of antimicrobial peptides in the bronchoalveolar lavage of patients with interstitial lung diseases. *Eur Respir J* 2021; 58: Suppl. 65, OA1208.
- 3 Cruz T, Bondonese A, Sembrat J, et al. Impaired lung NK activity in the lung of idiopathic pulmonary fibrosis patients. *Eur Respir J* 2021; 58: Suppl. 65, OA4332.
- 4 Nishikiori H, Hirota K, Suzuki T, et al. Validation of the artificial intelligence software to detect chronic fibrosing interstitial lung diseases in chest X-ray. *Eur Respir J* 2021; 58: Suppl. 65, OA1211.
- 5 Bendstrup E, Wijsenbeek M, Valenzuela C, et al. STARLINER study, disease behaviour assessed by a wide range of parameters including patient-reported outcomes (PRO) results. *Eur Respir J* 2021; 58: Suppl. 65, OA1207.
- 6 Froidure A, Bondue B, Dahlqvist C, et al. Clinical course of suspected familial versus sporadic IPF. Data from the PROOF-Next IPF registry. *Eur Respir J* 2021; 58: Suppl. 65, OA4328.
- 7 Matralis A, Karamitsakos T, Papaioannou O, et al. Biosynthesis and implementation of thyroid receptor beta (TRB) agonists (thyromimetics) for the treatment of pulmonary fibrosis. *Eur Respir J* 2021; 58: Suppl. 65, OA4334.
- 8 Cottin V, Seemayer C, Fagard L, et al. Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA). *Eur Respir J* 2021; 58: Suppl. 65, OA2904.
- 9 Porse S, Hoyer N, Skovhus Prior T, et al. Prognostic significance of dose reduction of antifibrotics in patients with IPF. *Eur Respir J* 2021; 58: Suppl. 65, OA1204.
- 10 Naccache J, Jouneau S, Didier M, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial. *Eur Respir J* 2021; 58: Suppl. 65, OA2903.
- 11 Tomos I, Dimakopoulou K, Manali E, et al. The effect of long-term personal air pollution exposure on the inflammatory mediators in idiopathic pulmonary fibrosis. *Eur Respir J* 2021; 58: Suppl. 65, OA1209.
- 12 Karamitsakos T, Mogulkoc N, Kreuter M, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. A retrospective multicenter study in Europe. *Eur Respir J* 2021; 58: Suppl. 65, OA1205.
- 13 Li N, Qiu L, Zeng C, et al. Bioinformatics analysis of differentially expressed genes and pathways in idiopathic pulmonary fibrosis. *Eur Respir J* 2021; 58: Suppl. 65, OA4331.
- 14 Kreuter M, Kabitz H, Hagemeyer L, et al. Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry. *Eur Respir J* 2021; 58: Suppl. 65, OA1206.
- 15 Bonella F, Vegas Sanchez M, Milan P, et al. Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study. *Eur Respir J* 2021; 58: Suppl. 65, OA2971.
- 16 Kreuter M, Maher T, Ichikado K, et al. Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial. *Eur Respir J* 2021; 58: Suppl. 65, OA2974.
- 17 Dos Reis Estrella D, Sacilotto Donaires F, Pinto Santos A, et al. Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD). *Eur Respir J* 2021; 58: Suppl. 65, OA4329.
- 18 Van der Vis JJ, Van der Smagt JJ, Van Batenburg A, et al. Pulmonary fibrosis in non-mutation carriers of families with short telomere syndrome gene mutations. *Eur Respir J* 2021; 58: Suppl. 65, OA4330.
- 19 Jee A, Stewart I, Youssef P, et al. A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study. *Eur Respir J* 2021; 58: Suppl. 65, OA2976.
- 20 Stock C, Kokosi M, Alfieri V, et al. Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD. *Eur Respir J* 2021; 58: Suppl. 65, PA2247.
- 21 Hoffmann-Vold A, Andersson H, Reisetter O, et al. Subclinical ILD is frequent and progresses across different connective tissue diseases. *Eur Respir J* 2021; 58: Suppl. 65, OA2973.

- 22 Emilsson O, Dessle A, Johannson H, *et al.* The severity of lung involvement in systemic sclerosis expressed as a Warrick score differs depending on the HRCT scan procedure. *Eur Respir J* 2021; 58: Suppl. 65, PA351.
- 23 Jayasinghe P, Wickramasinghe N, Krishnakumar P, *et al.* Characteristics of connective tissue diseases associated interstitial lung diseases – a single centre study in Sri Lanka. *Eur Respir J* 2021; 58: Suppl. 65, PA2540.
- 24 Samhoury B, Crowson C, Achenbach S, *et al.* Rheumatoid arthritis-associated interstitial lung disease: time trends. *Eur Respir J* 2021; 58: Suppl. 65, OA2969.
- 25 Oh J, Kim G, Cross G, *et al.* Automated quantification system predict a progressive phenotype in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J* 2021; 58: Suppl. 65, OA2968.
- 26 Denis A, Henket M, Gester F, *et al.* Incidence, prevalence and mortality of rheumatoid arthritis-associated interstitial lung disease: a retrospective study. *Eur Respir J* 2021; 58: Suppl. 65, PA2542.
- 27 Diou C, Debray M, Bancal C, *et al.* Progressive fibrosis is common in patients with Sjögren's syndrome and interstitial lung disease. *Eur Respir J* 2021; 58: Suppl. 65, PA2245.
- 28 Gouveia Cardoso C, Mendonça Almeida L, Fernandes AL, *et al.* Mortality risk prediction with ILD-GAP index in a portuguese chronic hypersensitivity pneumonitis cohort. *Eur Respir J* 2021; 58: Suppl. 65, PA2249.
- 29 Freitas Ferreira Araújo M, Carvalho A, Padrão E, *et al.* Disease behaviour and prognostic factors in hypersensitivity pneumonitis with UIP-like pattern. *Eur Respir J* 2021; 58: Suppl. 65, OA2970.
- 30 Groot Lipman K, de Gooijer C, Boellaard T, *et al.* Artificial intelligence-mediated diagnosis of asbestosis. *Eur Respir J* 2021; 58: Suppl. 65, OA2972.
- 31 Hoffmann-Vold A, Brunborg C, Tirelli F, *et al.* Impact and outcome of COVID-19 on SSc-ILD. *Eur Respir J* 2021; 58: Suppl. 65, PA2531.
- 32 Yamaya T, Hagiwara E, Baba T, *et al.* The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs. *Eur Respir J* 2021; 58: Suppl. 65, PA2254.
- 33 Baughman RP, Valeyre D, Korsten P, *et al.* ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J* 2021; 58: 2004079.
- 34 Paz S, Julian M, Siefker D, *et al.* Immunomodulatory protein ATYR1923 disrupts an *in vitro* model of sarcoid granuloma formation. *Eur Respir J* 2021; 58: Suppl. 65, OA3986.
- 35 Kraaijvanger R, Beijer E, Seldenrijk C, *et al.* mTORC1 signaling in granulomatous lesions is not specific for sarcoidosis. *Eur Respir J* 2021; 58: Suppl. 65, OA3979.
- 36 Nathan N, Montagne M, Macchi O, *et al.* Mineral exposures in pediatric sarcoidosis. *Eur Respir J* 2021; 58: Suppl. 65, OA3977.
- 37 Ronsmans S, Vandebroek E, Keirsbilck S, *et al.* Associations between occupational and environmental exposures and organ involvement in sarcoidosis: a retrospective case-case analysis. *Eur Respir J* 2021; 58: Suppl. 65, OA3978.
- 38 Knudsen K, Lehmann S, Nielsen R, *et al.* The pulmonary bacterial and fungal microbiota in sarcoidosis patients. *Eur Respir J* 2021; 58: Suppl. 65, OA3982.
- 39 Kahlmann V, Moor CC, Broos C, *et al.* Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis. *Eur Respir J* 2021; 58: Suppl. 65, OA3985.
- 40 Raasing L, Vogels O, Veltkamp M, *et al.* Effects of infliximab on FDG uptake and small fiber neuropathy symptoms in sarcoidosis patients. *Eur Respir J* 2021; 58: Suppl. 65, OA3984.
- 41 Frye B, Soriano D, Farin E, *et al.* FeV1 and body weight weight on LCQ in sarcoidosis patients. *Eur Respir J* 2021; 58: Suppl. 65, OA3983.
- 42 Lettieri S, Mariani F, Infusino C, *et al.* Lung fibrosis in pulmonary alveolar proteinosis (PAP): different stages of a syndrome or distinct diseases? *Eur Respir J* 2021; 58: Suppl. 65, PA2369.
- 43 Martins Baptista M, Melo N, Mota P, *et al.* Lymphangioliomyomatosis – experience of a university hospital. *Eur Respir J* 2021; 58: Suppl. 65, PA2371.
- 44 Garcia Moyano M, Urrutia A, Serrano L, *et al.* Lymphangioliomyomatosis and sirolimus: medium-term impact on pulmonary function. *Eur Respir J* 2021; 58: Suppl. 65, PA2372.
- 45 Naureen S, Faruqi S, Hart S, *et al.* Nitrofurantoin induced pulmonary fibrosis: a case series. *Eur Respir J* 2021; 58: Suppl. 65, PA2374.
- 46 Nasser M, Uzunhan Y, Hirschi S, *et al.* Idiopathic chronic obliterative bronchiolitis: a multicentric retrospective cohort. *Eur Respir J* 2021; 58: Suppl. 65, OA4236.
- 47 Lestelle F, Nasser M, Roux A, *et al.* Diffuse pulmonary non-amyloid light-chain deposition disease: phenotypes and outcome. *Eur Respir J* 2021; 58: Suppl. 65, OA4235.